According to iatroX platform data for September 2026, iatroX has been used 1 million times by over 50,000 verified clinicians across 40 countries, with adoption primarily in the UK and including over 15% of UK GPs. This article gives those figures a permanent, dated home, explains what they refer to, and describes the platform a new user finds today, which has grown considerably beyond the clinical reference tool most of that usage was built on.
The complete milestone
One million uses. Over 50,000 verified clinicians. Forty countries. Adoption primarily in the UK. Over 15% of UK GPs. Each figure has a different job across iatroX's wider coverage: the million uses is the headline milestone, the clinician count introduces the scale of the audience, the country count supports the international story, and the GP proportion anchors the UK general-practice picture. All four are attributed to the same source, iatroX platform data, September 2026.
Data note
Reporting date: September 2026. "Use" refers to [CONFIRM: definition, for example a completed Ask-iatroX query or a completed session across any platform feature]. "Verified clinician" refers to [CONFIRM: definition, for example a registered account whose professional status has been verified against a recognised register]. The UK GP percentage is calculated as [CONFIRM: numerator definition] against [CONFIRM: denominator, for example the GMC GP Register headcount at the reporting date]. Country count reflects [CONFIRM: basis, for example verified clinician accounts by registered country]. This note exists so the figures are checkable rather than merely stated, and it will be updated when the figures are.
The platform readers find today
The million uses were built substantially on Ask-iatroX, the free clinical reference that retrieves and synthesises UK guidance and SmPC information with linked sources. The platform today extends well beyond it. Question banks across more than forty examinations with adaptive sequencing and spaced repetition. A Socratic Tutor that opens on the question a learner just missed and works toward the misconception underneath. An exam-date-aware study planner that adapts to performance. iatroX Simulations, launched in September 2026 with eighteen examination-specific tracks. And CPD tools that turn learning into appraisal-ready evidence. The cumulative adoption figures describe the platform as a whole; they should not be read as applying separately to each newly launched feature, and this article does not present them that way.
The educational expansion
A proposed journey shows how the pieces connect. A clinician or student identifies a knowledge gap, a question that surprised them, a topic that keeps recurring. They understand it with Tutor, which asks what they assumed and identifies where the reasoning broke. They practise relevant questions, with spaced revisits scheduled by the planner. They rehearse its application in a simulation, a consultation or a reasoning encounter in which the corrected knowledge has to hold under time pressure. And the transcript shows whether it did. Each stage feeds the next; the value of the expansion is the connection, not any single tool.
The simulation proposition
iatroX Simulations, described in the September launch announcement, offers clinician-reviewed cases across eighteen examination-specific tracks, responsive voice and text interaction, transcript-linked feedback organised by domain, Tutor-led follow-up on the specific weakness each attempt reveals, and shared progress across the website and native apps. One complete simulation is free before subscribing. The simulations are covered in depth in iatroX's dedicated Simulations coverage, including the clinician-review methodology and what simulation does and does not replace.
Access and affordability
Ask-iatroX remains free, without a trial period or verification gate. The all-access subscription, £99 a year, equivalent to £8.25 a month billed annually, or £29 a month, covers the question banks, Tutor, planner, simulations and CPD together, with simulations included rather than sold separately. The adoption milestone is evidence of reach; it is not evidence of educational outcomes, and this article introduces the broader learning package as the next chapter of the product rather than as something the milestone proves.
Why this page exists
Every other iatroX article that mentions adoption links here rather than restating the figures with its own dates and definitions. When the figures change, this page changes, and the rest of the site inherits the correction. That is the honest way to use adoption data: one dated source, one set of definitions, one place to check.
Frequently asked questions
Are the 50,000 clinicians all UK-based?
No: adoption is primarily UK but spans 40 countries; the exact split is documented in the data note above as it is confirmed.
Do the million uses include Tutor, planner and simulations?
The cumulative figure describes the platform as a whole and was built substantially on Ask-iatroX; it should not be read as applying separately to features launched later.
Is the milestone evidence that iatroX improves learning or clinical outcomes?
No: it is evidence of reach and adoption, and this article says so; outcome claims require different evidence, which iatroX's methodology and evaluation coverage addresses separately.